General Hospital Psychiatry
Volume 27, Issue 4 , Pages 229-236 , July 2005

Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care

  • James E. Aikens, Ph.D.

      Affiliations

    • Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    • Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationCorresponding author. Department of Family Medicine, University of Michigan, Box 0708, Ann Arbor, MI 48109, USA. Tel.: +1 734 998 7120x320; fax: +1 734 998 7335.
    • ,
  • Kurt Kroenke, M.D.

      Affiliations

    • Department of Medicine, Division of General Internal Medicine and Geriatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • Regenstrief Institute, Indianapolis, IN 46202, USA
    • ,
  • Ralph W. Swindle, Ph.D.

      Affiliations

    • US Outcomes Research, U.S. Medical Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • Department of Psychology, Indiana University-Bloomington, Bloomington, IN 47405, USA
    • ,
  • George J. Eckert, M.A.S.

      Affiliations

    • Department of Medicine, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Received 26 January 2005 ,Revised 31 March 2005 ,Accepted 4 April 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Competing interests: James E. Aikens, PhD, is an employee of the University of Michigan and has served as an independent consultant to Pfizer, Inc. Kurt Kroenke, MD, has received research funding and honoraria as a consultant from Eli Lilly and Company, Pfizer, Inc., and Wyeth Pharmaceuticals. Ralph W. Swindle, PhD, is currently an employee of and stockholder in Eli Lilly and Company. Dr. Swindle has not received funding from any other source than Eli Lilly and Company over the last 5 years. Eli Lilly and Company funded the original ARTIST study, a randomized effectiveness trial of its SSRI antidepressant fluoxetine (Prozac), with paroxetine (Paxil) and sertraline (Zoloft). However, Eli Lilly and Company did not provide any funding for this manuscript.

☆☆ Author's contributions: JEA took primary responsibility for formulating the research questions, analyzing the data and writing all sections of the manuscript. KK and RWS each participated in the design and execution of ARTIST, assisted in interpreting the measures and results, and assisted JEA in writing the manuscript. GJE provided consultation to JEA on data analysis, managed the data and assisted in writing the manuscript. All authors read and approved the final manuscript.

PII: S0163-8343(05)00057-5

doi: 10.1016/j.genhosppsych.2005.04.001

General Hospital Psychiatry
Volume 27, Issue 4 , Pages 229-236 , July 2005

Article Tools

* Image Usage & Resolution